Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 81

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 81
---
 study involving 114 ACE2-transgenic mice to evaluate the short- and long-term benefits of the LPLT-based vaccination approach, which is expected to resume in Q4 2025 and conclude in the first  quarter of 2026. We have an exclusive license to these liposomal based vaccines and know-how, including potential applications other than SARS-CoV-2. The results of the study are necessary to establish proof of concept (POC) as well as to inform the provisional patent application that we are currently working on.  The results of this study are critical to determining the commercial viability of continued investment in this program. |

These product candidates
are in early stages of development and have not yet been clinically tested in the United States or elsewhere. Even if preclinical studies
show promising results, there is no guarantee that such pharmaceutical candidate will demonstrate sufficient efficacy or safety in human
populations.

The diagram below illustrates our product pipeline
across the various stages of development.

| * | See below Description of Business, Our Second                                                   
 Lead Candidate, Nano-Candesartan (nanoparticles-based ARB), is targeted for combination therapy 
 with an initial indication in pancreatic ductal adenocarcinoma (PDAC).                          |

<div align='center'>48

Our leading Product Candidate --Nano-Mupirocin</div>

Nano-Mupirocin is a novel NLP-based formulation
of a potent antibiotic mupirocin. Mupirocin is an antibiotic with a unique mode of action, not shared by any other therapeutically available
antibiotic. However, due to its rapid metabolic degradation following systemic administration and extensive plasma protein binding, the
therapeutic use of this well-established agent has been limited to topical application. The novel formulation of Nano-Mupirocin is specifically
designed to overcome the challenge of rapid metabolic degradation, enabling the development of a potent systemic therapy for life-threatening
antibiotic-resistant infections.

Antibiotic resistance occurs when bacteria change
in a way that makes antibiotics less effective or ineffective against them. This makes infections harder to treat and increases the risk
of disease spread, severe illness, disability, and death. Antibiotic resistance is driven by the misuse and overuse of antibiotics in
humans, animals, and plants, and is exacerbated by poverty and inequality.

Global Research on Antimicrobial Resistance (GRAM)
Project conducted and published by Cambridge University in 2024 demonstrated that globally antibiotic-resistant infections were directly
responsible for 1.45